

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Christof Westenfelder Confirmation No.: 6531
SERIAL NUMBER: 10/551,317 EXAMINER: WEHBE, Anne Marie
Sabrina
FILING DATE: August 21, 2006 ART UNIT: 1633
FOR: Stem-cell, precursor cell, or target cell-based treatment of multiorgan failure
and renal dysfunction

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages);
2. Modified Form PTO/SB/08(a) (4 pages); and
3. Copies of Cited References (2 Ref.).

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. **50-0311**, Reference No. **38447-201N01 US**.

Respectfully submitted,

/Sean M. Coughlin/

Ivor R. Elrifi, Reg. No. 39,529

Sean M. Coughlin, Reg. No. 48,593

Attorneys for Applicant

c/o MINTZ, LEVIN

Tel: (202) 585-3577

Fax: (617) 542-2241

Customer No. 30623

Dated: June 29, 2009

E-filed

Date of Deposit: June 29, 2009

Attorney Docket No. 38447-201N01 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Christof Westenfelder	Confirmation No.:	6531
SERIAL NUMBER:	10/551,317	EXAMINER:	WEHBE, Anne Marie Sabrina
FILING DATE:	August 21, 2006	ART UNIT :	1633
FOR:	Stem-Cell, Precursor Cell, or Target Cell-Based Treatment of Multiorgan Failure and Renal Dysfunction		

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is believed to be required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO/SB/08a to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **38447-201N01US**.

Respectfully submitted,

/Sean M. Coughlin/
Ivor R. Elrifi, Reg. No. 39,529
Sean M. Coughlin, Reg. No. 48,593
Attorneys for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (202) 585-3577
Fax: (617) 542-2241

Date: June 29, 2009

4653254v.1